Phone: 253-200-3166
Fax: 253-200-3167
What is Xofigo?
Xofigo (radium-223 dichloride) is a targeted radiopharmaceutical therapy used to treat metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones but not to other organs. It is designed to help reduce symptoms, delay disease progression, and improve quality of life.
How Xofigo Works
Xofigo contains radium-223, a radioactive isotope that mimics calcium in the body, allowing it to naturally seek out bone tissue, particularly in areas where cancer has spread. Once absorbed into the bone, Xofigo emits alpha radiation, which directly targets tumors by damaging the DNA of nearby cancer cells, leading to their destruction. Because alpha radiation has a short range of only a few cell diameters, it minimizes damage to surrounding healthy tissue, reducing potential side effects.
Administration
Administered as an intravenous (IV) injection
Given once every four weeks
A total of six doses is recommended for optimal results
Our healthcare team follows a comprehensive evaluation process to determine if Xofigo is the appropriate treatment for you. This decision is based on several key factors, including your medical history, cancer progression, and overall health status.